Ascendis Pharma A/S Bdr (A1SN34) Stock Price & News

A1SN34:BVMF

Ascendis Pharma A/S Bdr

R$95.22

0.00%

(0.00) 1D

Nov 9, 5:28:26 PM GMT-3 · BRL

All symbols

	Symbol	Price	Change	% Change

Last report

Nov 12, 2026

Fiscal period

Q3 2026

€1.71 / €1.65

+3.64%beat

Revenue / Est. (EUR)

369.66M / 366.36M

+0.90%beat

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in EUR

Loading Previous Earnings...

All values in EUR	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	247.50M	246.60M	339.28M	369.66M
Cost of goods sold	23.60M	17.52M	27.66M	28.31M
Cost of revenue	23.60M	17.52M	27.66M	28.31M
Research and development expenses	82.20M	59.04M	75.89M	69.92M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	139.31M	145.23M	173.34M	146.84M
Operating expense	221.51M	204.27M	91.16M	216.77M
Total operating expenses	245.11M	221.79M	118.82M	245.08M
Operating income	2.39M	24.81M	220.46M	124.58M
Other non operating income	-105.57M	-	-	7.71M
EBT including unusual items	-26.70M	-48.18M	230.09M	113.37M
EBT excluding unusual items	-34.21M	-48.18M	230.09M	113.37M
Income tax expense	6.86M	-677.52M	23.12M	39.40M
Effective tax rate	-25.68%	1,406.31%	10.05%	34.75%
Other operating expenses	-	-	-158.07M	-
Net income	-33.56M	629.34M	206.97M	73.97M
Net profit margin	-13.56%	255.21%	61.00%	20.01%
Earnings per share	-0.55	0.27	0.90	1.71
Interest and investment income	64.06M	4.52M	19.96M	-
Interest expense	-74.65M	-67.26M	-14.17M	-12.04M
Net interest expenses	-10.59M	-62.74M	5.79M	-12.04M
Depreciation and amortization charges	-	-	-	-
EBITDA	3.60M	29.03M	225.03M	129.22M
Gain or loss from assets sale	-	-	21.00K	-

Finance